Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence by Priestman, D, Welford, R, Platt, F, Muhlemann, A, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Baldoni, D, Probst, M

Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence by Welford, R, Mühleman, A, Priestman, D, Garzotti, M, Deymier, C, Ertel, E, Iglarz, M, Morand, O, Priestman, D, Platt, F, Probst, M

An international multicentre validation experiment for MOG antibodies by Reindl, M, Schanda, K, Woodhall, M, Tea, F, Ramanathan, S, Teegen, B, Sagen, J, Fryer, J, Mills, J, Mindorf, S, Ritter, N, Krummrei, U, Stoecker, W, Eggert, J, Rostasy, K, Berger, T, Irani, S, Dale, R, Probst, C, Brilot, F, Probst, M, Pittock, S, Waters, P